Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The way that miR-377 inhibits cells that cause prostate cancer.

2.

Cancer detection recovered following pandemic disruptions

3.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

4.

Three out of ten breast cancers detected between screenings, study finds

5.

Screening for prostate cancer: is it time to give up digital rectal examination?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot